Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Phost'in Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiho Pharmaceutical and Phost\u2019in Therapeutics Announce an Option and License Agreement on the First-in-Class GnT-V Inhibitor PhOx430","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Phost'in Therapeutics

    Menu

    Phost'in Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Phost'in Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Taiho Pharmaceutical and Phost’in Therapeutics Announce an Option and License Agreement on the First-in-Class GnT-V Inhibitor PhOx430

              Details:

              Under the agreement, Taiho will obtain option rights for PhOx430, a first-in-class small molecule targeting GnT-V and additional undisclosed compounds and to exclusively develop and commercialize the compounds in Japan and certain other territories in Asia.

              Lead Product(s): PhOx430

              Therapeutic Area: Oncology Product Name: PhOx430

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Taiho Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY